We have previously shown that absence of the mouse mdr1a (also called mdr3) Pglycoprotein in mdr1a (-/-) "knockout" mice has a profound effect on the tissue distribution and elimination of vinblastine and ivermectin, and hence on the toxicity of these compounds. We show here that the mouse mdr1a and the human MDR1 P-glycoprotein actively transport ivermectin, dexamethasone, digoxin, and cyclosporin A and, to a lesser extent, morphine across a polarized kidney epithelial cell layer in vitro. Injection of these radio-labeled drugs in mdr1a (-/-) and wild-type mice resulted in markedly (20-to 50-fold) higher levels of radioactivity in mdr1a (-/-) brain for digoxin and cyclosporin A, with more moderate effects for dexamethasone (2-to 3-fold) and morphine (1.7-fold). Digoxin and cyclosporin A were also more slowly eliminated from mdr1a (-/-) mice. Our findings show that P-glycoprotein can be a major determinant for the pharmacology of several medically important drugs other than anti-cancer agents, especially in the blood-brain barrier. These results may explain a range of pharmacological interactions observed between various drugs in patients.
Introduction
Upon selection with a single cytotoxic drug, mammalian cancer cells can develop resistance against a range of drugs with different structures and intracellular targets. This phenomenon, called multidrug resistance, can be caused by P-glycoproteins, 140-170-kD plasma membrane proteins that actively extrude a wide range of amphiphilic hydrophobic drugs from the cell (1) (2) (3) (4) (5) . Many of these drug substrates are toxic compounds of natural or semisynthetic origin that are extensively used in the chemotherapy of cancer (e.g., Vinca alkaloids, anthracyclines, epipodophyllotoxins, taxanes) but also for a variety of other medical purposes such as immunosuppression (cyclosporin A, FK506) and treatment of heart disease (verapamil, digoxin).
Humans have one drug-transporting P-glycoprotein (MDR1), which is prominent in the brush border of renal proxi-mal tubules, in the biliary membrane of hepatocytes, in the apical membrane of mucosal cells in the intestine, in capillary endothelial cells of brain and testis, in adrenal gland and in placental trophoblasts (6) (7) (8) . This distribution suggested that MDR1 P-glycoprotein can protect the organism against toxic xenobiotic compounds, by excreting these compounds into urine, bile, and the intestinal lumen, and by preventing their accumulation in critical organs such as brain or testis. In contrast to humans, mice have two genes encoding drug-transporting Pglycoproteins, mdrla (also called mdr3) and mdrlb (also called mdrl), respectively (2, 9, 10) . The mouse mdrla gene is predominantly expressed in intestine, liver, and blood capillaries of brain and testis, whereas the mdrlb gene is predominantly expressed in adrenal, placenta, ovarium and (pregnant) uterus. Similar levels of mdrla and mdrlb expression are found in kidney (11) (12) (13) (14) . These data suggest that mdrla and mdrlb in the mouse together fulfil the same function as MDRJ in humans.
Studies of MDR1 protein and RNA levels in clinical tumor samples indicate that this protein may be relevant for intrinsic or acquired MDR in a range of tumor types (e.g., [15] [16] [17] . This led to an extensive search for P-glycoprotein inhibitors. Many compounds with low cytotoxicity can inhibit P-glycoprotein activity, for instance verapamil, quinidine, cyclosporin A and its non-immunosuppressive analogue PSC833 (18) (19) (20) (21) . There is currently great interest in the co-administration of these socalled reversal agents in patients to reduce P-glycoprotein-mediated drug resistance of tumors during chemotherapy. Many phase I and phase II clinical trials to test the feasibility of this approach are now in progress (22) (23) (24) (25) . One major concern in this approach is the effect that P-glycoprotein inhibitors will have on the normal function of the drug-transporting P-glycoproteins. To learn more about the physiological and pharmacological role of these proteins, we have recently generated a mouse strain with a genetic disruption of the mdrla gene (mdrla (-/-) mice; 14).
The mdrla (-/-) mice provided a striking confirmation of the protective role of P-glycoprotein. These mice, which do not have detectable P-glycoprotein at the blood-brain barrier, were 100-fold more sensitive to the neurotoxic pesticide ivermectin, threefold more sensitive to the anti-cancer agent vinblastine, and they accumulated much higher levels of these drugs in their brain. In addition, they displayed overall increased accumulation of these compounds in tissues and plasma, and decreased elimination ( 14) . Many other drugs are known to be substrates of P-glycoprotein in vitro, including morphine, one of the most widely used analgetics (26) ; dexamethasone, an anti-inflammatory and glucocorticoid drug (27) ; digoxin, a heart glycoside that is widely used in the treatment of congestive heart failure (28); and cyclosporin A, an agent that has revolutionized organ transplantation by its ability to suppress allograft rejection (29) . We have therefore tested whether the in vivo distribution of these medically important drugs (30) is also affected by the absence of mdrla P-glycoprotein. Because the substrate specificity of P-glycoprotein variants can differ substantially (31, 32), we also compared the ability of the human MDR1 and the mouse mdrla P-glycoprotein to transport these drugs in vitro. This enables us to assess whether the MDR1 Pglycoprotein could affect the distribution of these drugs in humans in a similar manner as the mdrla P-glycoprotein in mice. Transport assays. Transport assays were carried out as described (27) with minor modifications. Complete medium including L-glutamine, penicillin, streptomycin, and fetal calf serum was used throughout. Cells were seeded on microporous polycarbonate membrane filters (3.0 Am pore size, 24.5-mm diameter, Transwell'm 3414, Costar0) at a density of 2 x 106 cells per well for LLC-PKl, L-MDRl, and L-mdrla, respectively. The cells were grown for 3 d in complete medium with one medium replacement. 1-2 h before the start of the experiment medium at both the apical and the basal side of the monolayer was replaced with 2 ml of complete medium. The experiment was started (t = 0) by replacing the medium at either the apical or the basal side of the cell layer with 2 ml of complete medium containing the appropriate concentration of the radiolabeled drug (at 0.25 ACi/ml), and '4C-labeled inulin (0.025 ,uCi/ml, 4.2 AM). The cells were incubated at 37°C in 5% CO2, and 50-Al aliquots were taken from each compartment at 1, 2, 3, and 4 h. The appearance of radioactivity in the opposite compartment was measured and presented as the fraction of total radioactivity added at the beginning of the experiment. Directional the opposite compartment and was always < 1.5% of total radioactivity per h. Drug distribution studies. Drug distribution experiments were carried out as described ( 14) . Male mice between 9 and 14 wk of age were analyzed using 3, 4, or 5 mice in each group. Drugs for intravenous injection were formulated such, that S Al drug solution per gram body weight was injected into the tail vein of mice lightly anesthetized with diethyl ether (injection time: 5 s). Unlabeled drug stocks were diluted in sterile 5% (wt/vol) D-glucose solution to obtain the appropriate concentration for injection (0.2 mg/ml or 0.04 mg/ml). Morphine.HCl stock (1 mg/ml) was dissolved in 5% D-glucose, dexamethasone and digoxin stocks (1 mg/ml each) were dissolved in 1,2-propanediol, and cyclosporin A (50 mg/ml) was dissolved in polyoxyethylated ricinus oil (650 mg/ml) and ethanol (33% vol/vol). Labeled drugs were added after appropriate dilution of the drug stocks. Between 1 and 2.5 OCi was injected per mouse. At specific time points, mice were anesthetized and completely bled by orbital traction, thus removing most of the blood content of tissues. Heparin-plasma was obtained from the collected blood by centrifugation. Tissues were collected, weighed, and homogenized in 4% (wt/vol) bovine serum albumin. Blood-rich organs such as liver were dabbed on filter paper to remove most of the remaining blood. The contents of stomach, small intestine and colon were removed before homogenizing, whereas the gall bladder was processed with its bile content included. 200 sl aliquots of plasma or homogenized tissue were transferred to Ultima gold counting fluid (Packard, Meriden, CT) and radioactivity was determined by liquid scintillation counting. The statistical significance of differences found between radioactivity levels in tissues of wild-type and mdrla (-/-) mice was assessed using Student's two-tailed t test.
Methods

Results
In vitro transport of drugs by the mouse mdrla and the human MDRJ P-glycoprotein. To obtain a qualitative assessment of the capability of the mouse mdrla and the human MDR1 Pglycoprotein to translocate substrate drugs, we transfected the polarized pig kidney epithelial cell line LLC-PK1 with expression vectors containing mdrla or MDRI cDNA. Clones readily growing at high vincristine concentrations (640 nM) were picked and their P-glycoprotein content was tested on an immunoblot. Fig. 1 Time (h) P-glycoprotein consistently migrated somewhat faster than the MDR1 P-glycoprotein, possibly owing to less extensive glycosylation, as the protein backbones have the same size. A small amount of porcine P-glycoprotein was detected in the parental cell line (27) . These clones (LLC-PK1, L-MDR1, and Lmdrla) were used to measure the transepithelial transport of radiolabeled compounds as described (27, 37) . For details see Methods. Fig. 2 illustrates that ivermectin, dexamethasone, digoxin and cyclosporin A were all readily transported in a polarized fashion by both the MDR1 and the mdrla P-glycoprotein. This is shown by the increased translocation from the basal to the apical side, and the decreased translocation from the apical to the basal side in the transfectants. The direct demonstration of ivermectin transport by both P-glycoproteins confirms our prediction based on ivermectin tissue distribution and toxicity in mdrla (-/-) mice (14) and indicates that the MDR1 Pglycoprotein will also affect ivermectin handling in humans. Morphine was transported to a moderate extent by the mdrla clone, and marginally by the MDR1 clone. Lowering the morphine concentration from 2 ,M to 50 nM or even 5 nM did not improve the fractional transport capacity (not shown), indicating that the low transport rate observed was rather due to inefficient translocation of morphine (low apparent Vm,,), than due to saturation of P-glycoprotein activity. Relatively inefficient transport of morphine as detected by reduced accumulation in cells was also reported for hamster P-glycoprotein (26) . Like for morphine, lowering the concentration of dexamethasone or digoxin to 50 or 100 nM did not significantly alter the fractional transport by these clones (not shown), indicating that the apparent Km for these drugs in this system is higher than 2 4M.
Vectorial transport by the human MDR1 P-glycoprotein across epithelial cell layers was demonstrated before for dexamethasone, digoxin, and cyclosporin A (27) (28) (29) , although the clearly decreased translocation of cyclosporin A from apical to basal compartment (see Fig. 2 ) was not observed previously (29, 38) . This is of importance, as the apical to basal drug transport more or less models the situation relevant for the accumulation of drugs in the brain in vivo (see below).
The data for the parental cell line also give an indication for the ease with which different compounds can passively diffuse through an epithelial cell layer: ivermectin, morphine and digoxin diffused with a moderate rate (3-4% per hour), cyclosporin A with a higher rate (5-6% per hour), and dexamethasone with a still higher rate (7.5-9% per hour). These intrinsic properties of drugs may also affect their distribution and excretion properties in intact organisms, and the extent to which their handling is affected by MDRl-type P-glycoproteins.
Distribution of drugs in mdrla (-/-) and (+/+) mice. We have shown previously that mdrla (-/-) mice display a much higher accumulation of ivermectin and vinblastine in the brain than wild-type mice. In addition, vinblastine was eliminated more slowly from plasma and from several other organs such as heart, kidney, and liver (14) . These findings indicate that a marked effect of mdrla deficiency in the blood-brain barrier for a certain drug will probably predict an overall effect on tissue distribution and pharmacokinetics of this drug.
To rapidly screen whether the handling of certain drugs will be affected by P-glycoprotein activity in vivo, we administered radiolabeled drugs intravenously, to mtdrla (-/-) and wildtype mice, and determined the tissue distribution of total radioactivity at certain time points. To limit complications by metabolism of drugs, we concentrated on a relatively early time point (4 h after injection). Table I shows the results obtained with a low dose of [3H] morphine (0.2 mg/kg). Whereas in vitro the mdrla P-glycoprotein demonstrated a limited transport of this drug, no significant differences were observed between rmdrla (-I-) and (+/+) mice, except for the brain of mdrla (-/-) mice which accumulated somewhat more [3H] morphine as detected by total radioactivity. The effect was limited, and in line with this finding, a small-scale acute toxicity test indicated that mdrla (-/ -) mice have an LD50 for morphine comparable with that of wild-type mice (data not shown).
For [3H]dexamethasone at low dose (0.2 mg/kg) we observed a significant difference in brain concentration 4 h after injection, although it was fairly moderate (2.5-fold, see Table  II ). At the same time, plasma levels were comparable between mdrla (-/-) and (+/+) mice, and the levels in all other tissues measured did not differ significantly. As dexamethasone fairly rapidly permeates membranes (see Fig. 2 ) we considered the possibility that it might have diffused already from the brain even in the absence of mdrla P-glycoprotein. We therefore (35-fold) higher accumulation of total radioactivity in brain of mdrla (-/-) mice compared to wild-type mice 4 h after injection (Table Ill) . At the same time, the concentration in plasma and in most tissues was roughly twofold higher in mdrla (-/ -) mice, suggesting an overall decreased elimination rate of this drug. These differences are rather similar to those seen previously with vinblastine at a dose of 1 mg/kg (14) Results are expressed as means±SD (n-1) in ng/g tissue ([3H]cyclosporin A equivalent). Three mice were analyzed in each group. * P < 0.05; t P < 0.01; I P < 0.001.
(lymphocytes) did not demonstrate clear differences in accumulation independent of the plasma concentration.
Discussion
Our results indicate that the tissue distribution and pharmacokinetics of the heart glycoside digoxin and the immunosuppressive drug cyclosporin A are strongly affected by the mouse mdrla P-glycoprotein activity. Tissue distribution of the glucocorticoid dexamethasone is moderately affected, whereas morphine handling appears to be hardly affected in vivo. In vitro, the human MDR1 P-glycoprotein demonstrated a comparable ability to transport ivermectin, dexamethasone, digoxin and cyclosporin A as the mdrla P-glycoprotein (Fig. 2) , suggesting that also in humans the handling of these drugs can be markedly affected by P-glycoprotein activity. In fact, the drug distribution and pharmacokinetic effects in the mdrla (-/-) mice will probably be limited by the continuing presence of the mdrlb P-glycoprotein, especially as this protein is upregulated in liver and kidney of mdrla (-/-) mice (14) . Partial or complete blocking of the single drug-transporting MDR1 P-glycoprotein in humans might therefore have even more outspoken pharmacological effects than those observed in mdrla (-/-) mice. The limited effects on morphine handling by the mdria Pglycoprotein in mice, combined with the very low in vitro transport by the MDR1 P-glycoprotein suggest that this drug will be hardly affected by P-glycoprotein activity in humans. However, it should be noted that some of the compounds tested may undergo relatively rapid metabolism in mice. If the resulting (radiolabeled) metabolites are not affected by P-glycoprotein, we may underestimate the effect of the absence of mdria Pglycoprotein by analyzing total radioactivity. This could for instance apply to morphine and dexamethasone. A definitive assessment of the significance of P-glycoprotein for the distribu- tion of these compounds must therefore await a more extensive analysis using specific detection of the parent drugs. Our finding that the in vivo handling of both digoxin and cyclosporin A is strongly affected by MDR1-type P-glycoprotein sheds new light on many pharmacological interactions that have been observed in clinical practice. The heart glycoside digoxin, widely used in the treatment of congestive heart failure, has a narrow therapeutic window: a moderate increase in concentration relative to the therapeutic plasma level will result in dangerous toxicity to the heart. Interestingly, co-administration of many other drugs was found to result in increased plasma levels of digoxin. Some striking examples are the anti-arrhythmic drugs quinidine and amiodarone, the calcium channel blockers verapamil and diltiazem, and the anti-malarial drug quinine (30) . In retrospect, most of these drugs turn out to be compounds that can inhibit P-glycoprotein activity (21 ). In fact, some of these drugs (verapamil, quinidine, quinine) have even been used in clinical trials because of their ability to reverse Pglycoprotein-mediated multidrug-resistance in chemotherapy resistant tumors (24) . In view of our findings it is likely that the observed drug interactions are due at least in part to inhibition of P-glycoprotein activity by the co-administered drugs, resulting in altered tissue distribution and diminished elimination of digoxin. This possibility was previously proposed by Tanigawara et al. (28) based on their finding that the human MDR1 Pglycoprotein can transport digoxin in vitro.
The digoxin concentration in brain is very markedly affected in mdrla (-/-) mice. In view of the side effects of digoxin treatment on the central nervous system of humans (30) , one might expect severely increased toxicity of digoxin in mndrla (-/ -) mice. However, a small-scale oral toxicity test revealed only a roughly fourfold increase in sensitivity (not shown). This is probably due to the fact that the mouse form of the pharmacological target of digoxin (the Na+/K+ -ATPase) is unusually resistant to digoxin (39) . Digoxin toxicity in mice is therefore fundamentally different from that in humans.
A more or less similar situation as for digoxin holds true for the immunosuppressive drug cyclosporin A. Whereas this drug has so far been used mainly in relation to P-glycoprotein for its ability to inhibit the transport of other drugs (even in clinical trials of MDR reversal, see reference 24), it now appears to be itself an excellent P-glycoprotein substrate in vivo: its pharmacological disposition is to a considerable extent influenced by P-glycoprotein activity. Drugs that can increase plasma levels of cyclosporin A upon co-administration include ketoconazole, erythromycin, diltiazem, nicardipine, and verapamil (30; manufacturer's information). All of these drugs have been shown to act as P-glycoprotein reversal agents (21, 40) . In fact, in some clinical settings, after renal transplantation, diltiazem is purposely co-administered with cyclosporin A to allow an effective plasma level of this expensive drug to be reached with lower drug dosages. As cyclosporin A is mainly eliminated via the liver, it is thought that these drug interactions are the consequence of competition for degradation by cytochrome P450(3A) enzymes in the liver (30, (41) (42) (43) . However, our data show that competition for P-glycoprotein activity might also contribute to the observed effects. Following this line of reasoning, the pharmacological behavior of cyclosporin A coadministered as a reversal agent during chemotherapy with cytotoxic P-glycoprotein substrates might in turn also be affected by the presence of these drugs, depending on their relative ability to compete for P-glycoprotein transport.
The marked tissue distribution effects observed for cyclosporin A and (to a lesser extent) dexamethasone indicate that the accumulation of these compounds in individual cells in the organism is also affected by the presence of P-glycoprotein in the membrane of these cells. For cyclosporin A, this may in itself be of importance, as the clinical targets of this immunosuppressive drug (lymphocytes: CD4+ helper T cells and CD8+ suppressor or cytolytic T cells) (44) also contain functional P-glycoprotein (45) . Variation in P-glycoprotein levels in these cells between individual patients might explain in part the somewhat variable plasma levels of cyclosporin A needed to obtain an effective suppression of allograft rejection. One might even speculate that the beneficial effect of adding diltiazem to cyclosporin A regimens in renal transplantation (44) is partly the consequence of improved penetration of cyclosporin A into its target cells. As for dexamethasone, it has been shown that in a mouse thymoma cell line the mdrlb P-glycoprotein can confer resistance against this drug (46) . Clinical efficacy of this drug may therefore also be affected by P-glycoprotein at the cellular level.
Taken together, our results confirm and extend the potential in vivo pharmacological importance of MDR1-type P-glycoproteins for many different drugs, including both those excreted primarily via the kidney (e.g., digoxin) and those eliminated primarily via the liver (e.g., cyclosporin A). Hopefully, this knowledge will contribute to the improved pharmacological treatment of cancer as well as other diseases.
